Alterome Therapeutics Inc. has synthesized RAC-α serine/threonine-protein kinase (AKT1; PKB α) (E17K mutant) inhibitors reported to be useful for the treatment of cancer.
Alterome Therapeutics Inc. has identified new RAC-α serine/threonine-protein kinase (AKT1; PKB-α) E17K mutant)inhibitors reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results